Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias.
Nikitin E, Kislova M, Morozov D, Belyakova V, Suvorova A, Sveshnikova J, Vyscub G, Matveeva I, Shirokova M, Shipaeva A, Klitochenko T, Makarovskaya P, Dmitrieva E, Biderman B, Sudarikov A, Obukhova T, Samoilova O, Kaplanov K, Konstantinova T, Mayorova O, Poddubnaya I, Ptushkin V. Nikitin E, et al. Among authors: poddubnaya i. Leukemia. 2023 Jul;37(7):1464-1473. doi: 10.1038/s41375-023-01891-3. Epub 2023 May 18. Leukemia. 2023. PMID: 37202442 Free PMC article.
Proposed rituximab biosimilar BCD-020 versus reference rituximab for treatment of patients with indolent non-Hodgkin lymphomas: An international multicenter randomized trial.
Poddubnaya IV, Alekseev SM, Kaplanov KD, Lukavetskyy LM, Rekhtman GB, Dolai TK, Attili VSS, Bermúdez CD, Isaev AA, Chernyaeva EV, Ivanov RA. Poddubnaya IV, et al. Hematol Oncol. 2020 Feb;38(1):67-73. doi: 10.1002/hon.2693. Epub 2020 Jan 13. Hematol Oncol. 2020. PMID: 31724191 Clinical Trial.
[Role of clustered HER2/neu amplification as a marker for a special sensitivity to neoadjuvant anti-HER2 therapy with trastuzumab in patients with stage II-III breast cancer].
Kolyadina IV, Zavalishina LE, Ganshina IP, Andreeva YY, Frank GA, Gordeeva OO, Zhukova LG, Meshcheryakov AA, Savelov NA, Tuzova EA, Morozov DA, Poddubnaya IV. Kolyadina IV, et al. Among authors: poddubnaya iv. Arkh Patol. 2019;81(6):56-62. doi: 10.17116/patol20198106156. Arkh Patol. 2019. PMID: 31851193 Russian.
[Monoclonal gammopathy of renal significance: consensus of hematologists and nephrologists of Russia on the establishment of nosology, diagnostic approach and rationale for clone specific treatment].
Smirnov AV, Afanasyev BV, Poddubnaya IV, Dobronravov VA, Khrabrova MS, Zakharova EV, Nikitin EA, Lysenko Kozlovskaya LV, Bobkova IN, Rameev VV, Batyushin MM, Moiseev IS, Darskaya EI, Pirogova OV, Mendeleeva LP, Biryukova LS. Smirnov AV, et al. Among authors: poddubnaya iv. Ter Arkh. 2020 Sep 1;92(7):10-22. doi: 10.26442/00403660.2020.07.000659. Ter Arkh. 2020. PMID: 33346441 Russian.
Genetic markers associated with adverse reactions of radioiodine therapy in thyroid cancer patients.
Denisenko NP, Kachanova AA, Sychev IV, Shuev GN, Perfilieva OM, Mukhamadiev RH, Kazakov RE, Milyutina OI, Konenkova OV, Ryzhkin SA, Zhmaeva EM, Kirienko SL, Ivashchenko DV, Bure IV, Ametov AS, Poddubnaya IV, Mirzaev KB, Sychev DA. Denisenko NP, et al. Among authors: poddubnaya iv. Drug Metab Pers Ther. 2023 Jun 30;38(3):255-265. doi: 10.1515/dmpt-2023-0007. eCollection 2023 Sep 1. Drug Metab Pers Ther. 2023. PMID: 37708952
Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study.
Witzens-Harig M, Foá R, Di Rocco A, van Hazel G, Chamone DF, Rowe JM, Arcaini L, Poddubnaya I, Ho AD, Ivanova V, Vranovsky A, Thurley D, Oertel S. Witzens-Harig M, et al. Among authors: poddubnaya i. Ann Hematol. 2014 Oct;93(10):1717-24. doi: 10.1007/s00277-014-2103-3. Epub 2014 May 14. Ann Hematol. 2014. PMID: 24824768 Clinical Trial.
Genetic markers associated with adverse reactions of radioiodine therapy in thyroid cancer patients.
Denisenko NP, Kachanova AA, Sychev IV, Shuev GN, Perfilieva OM, Mukhamadiev RH, Kazakov RE, Milyutina OI, Konenkova OV, Ryzhkin SA, Zhmaeva EM, Kirienko SL, Ivashchenko DV, Bure IV, Ametov AS, Poddubnaya IV, Mirzaev KB, Sychev DA. Denisenko NP, et al. Among authors: poddubnaya iv. Drug Metab Pers Ther. 2023 Jun 30. doi: 10.1515/dmdi-2023-0007. Online ahead of print. Drug Metab Pers Ther. 2023. PMID: 37381702
13 results